DiaMonTech AG

  • WKN: A255G4
  • ISIN: DE000A255G44
  • Land: Deutschland

Nachricht vom 16.09.2019 | 09:00

DiaMonTech: Innovative, pain-free blood glucose monitoring to improve the quality of life of diabetes patients in Germany with the help of local pharmacies

DGAP-News: DiaMonTech GmbH / Key word(s): Alliance

16.09.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


DiaMonTech: Innovative, pain-free blood glucose monitoring to improve the quality of life of diabetes patients in Germany with the help of local pharmacies

Berlin, 16 September 2019 - Germany's pharmacists want to ease life for millions of diabetics by offering them pain-free blood glucose monitoring without taking blood as soon as possible. The Deutscher Apothekerverband e. V. (DAV; German Association of Pharmacists) and DiaMonTech GmbH, a young and innovative medical technology company, intend a strategic cooperation to significantly improve the care of diabetes patients and to take an innovative step into the future.

"The Deutscher Apothekerverband is an important partner for us as the umbrella organization with more than 19,000 pharmacies in Germany. The signing of the Letter of Intent confirms the mutual will to cooperate in a trusting and productive manner. Diabetes patients need personal care and access to the latest technology. They should be able to get both from the local pharmacy." says Thorsten Lubinski, co-founder and CEO of DiaMonTech GmbH.

The DAV and DiaMonTech are initially striving to carry out practical tests of the already CE-certified "DMT Base" in selected pharmacies. The "DMT Base" is currently optimized for use in professional environments (e.g. diabetes centers). The patient places his finger on a sensor field for a few seconds and the blood sugar is shown categorized on a display. The blood sugar level can be measured precisely and painlessly without a drop of blood. DiaMonTech thus offers a solution for diabetes patients worldwide that offers them the opportunity to significantly improve their quality of life.

The smaller "DMT Pocket" is currently in development with market launch expected by the end of 2020. This device is supposed to have the size of a smartphone and could therefore become a constant accompaniment for diabetes patients. In Germany alone, around 7.2 million people are currently affected.

About DiaMonTech
DiaMonTech GmbH is a medical technology company that specializes in the development, design and sale of products for medical diagnostics. The patented photothermal diagnostic technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain.

More information about DiaMonTech can be found at www.diamontech.de.

Press contact
Alexander Neblung
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
E-mail diamontech@kirchhoff.de



16.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Event im Fokus

14.-15.10.2020 Fachkonferenzen Finanzdienstleistungen und Technologie

11.-12.11.2020 Fachkonferenzen Software/IT und Branchenmix

Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen könnten die Fachkonferenzen im Herbst/Winter ggf. auch virtuell stattfinden.

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Continental AG veröffentlicht vorläufige Kennzahlen für das 3. Quartal 2020 und berücksichtigt nicht zahlungswirksame Wertminderungen sowie Restrukturierungsaufwendungen

21. Oktober 2020, 17:57

Aktueller Webcast

HelloFresh SE

Q3 2020 Results Webcast

03. November 2020

Aktuelle Research-Studie

Nynomic AG

Original-Research: Nynomic AG (von Montega AG): Kaufen

22. Oktober 2020